GREENFIELD, Ind., May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
On Thursday, May 22, Jeff Simmons, president and CEO, will participate in the BNP Paribas 2nd Annual Animal Health Day at 12:00 p.m. ET.
On Thursday, May 29, Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat at Stifel 2025 Jaws & Paws Conference at 8:00 a.m. ET.
Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will be available for a limited time at the conclusion of each event.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$21.79 |
| Daily Change: | 0.50 2.35 |
| Daily Volume: | 2,880,154 |
| Market Cap: | US$10.830B |
November 21, 2025 November 13, 2025 November 05, 2025 October 24, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
